The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva, Anna Sureda, Laura Montejano et al.|Blood|2009Cited by 75
Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple MyelomaJuan José Lahuerta, Jesús F. San Miguel, Carlos Grande et al.|Leukemia & lymphoma/Leukemia and lymphoma|2002Cited by 54
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.María‐Victoria Mateos, Jesús F. San Miguel, Albert Oriol et al.|Blood|2009Cited by 45